Chengdu Easton Biopharmaceuticals (SHA:688513), through unit Shanghai Chaoyang Pharmaceutical, enrolled the first subject for the clinical trial of HP-002 tablets, according to a Shanghai bourse filing on Thursday.
The trial, which is in phase I/II, invited patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The drug's safety and tolerability will be tested in the patients.
The pharmaceutical company's shares jumped 2% during the afternoon trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.